156 related articles for article (PubMed ID: 36627374)
1. Nanoformulation of the K-Ras(G12D)-inhibitory peptide KS-58 suppresses colorectal and pancreatic cancer-derived tumors.
Sakamoto K; Qi Y; Miyako E
Sci Rep; 2023 Jan; 13(1):518. PubMed ID: 36627374
[TBL] [Abstract][Full Text] [Related]
2. The K-Ras(G12D)-inhibitory peptide KS-58 suppresses growth of murine CT26 colorectal cancer cell-derived tumors.
Sakamoto K; Lin B; Nunomura K; Izawa T; Nakagawa S
Sci Rep; 2022 May; 12(1):8121. PubMed ID: 35581303
[TBL] [Abstract][Full Text] [Related]
3. Generation of KS-58 as the first K-Ras(G12D)-inhibitory peptide presenting anti-cancer activity in vivo.
Sakamoto K; Masutani T; Hirokawa T
Sci Rep; 2020 Dec; 10(1):21671. PubMed ID: 33303890
[TBL] [Abstract][Full Text] [Related]
4. K-Ras(G12D)-selective inhibitory peptides generated by random peptide T7 phage display technology.
Sakamoto K; Kamada Y; Sameshima T; Yaguchi M; Niida A; Sasaki S; Miwa M; Ohkubo S; Sakamoto JI; Kamaura M; Cho N; Tani A
Biochem Biophys Res Commun; 2017 Mar; 484(3):605-611. PubMed ID: 28153726
[TBL] [Abstract][Full Text] [Related]
5. Rasfonin, a novel 2-pyrone derivative, induces ras-mutated Panc-1 pancreatic tumor cell death in nude mice.
Xiao Z; Li L; Li Y; Zhou W; Cheng J; Liu F; Zheng P; Zhang Y; Che Y
Cell Death Dis; 2014 May; 5(5):e1241. PubMed ID: 24853419
[TBL] [Abstract][Full Text] [Related]
6. Aphanin, a triterpenoid from Amoora rohituka inhibits K-Ras mutant activity and STAT3 in pancreatic carcinoma cells.
Rabi T; Catapano CV
Tumour Biol; 2016 Sep; 37(9):12455-12464. PubMed ID: 27333990
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
[TBL] [Abstract][Full Text] [Related]
8. ERK2-regulated TIMP1 induces hyperproliferation of K-Ras(G12D)-transformed pancreatic ductal cells.
Botta GP; Reichert M; Reginato MJ; Heeg S; Rustgi AK; Lelkes PI
Neoplasia; 2013 Apr; 15(4):359-72. PubMed ID: 23555182
[TBL] [Abstract][Full Text] [Related]
9. K-Ras
Feng H; Zhang Y; Bos PH; Chambers JM; Dupont MM; Stockwell BR
Biochemistry; 2019 May; 58(21):2542-2554. PubMed ID: 31042025
[TBL] [Abstract][Full Text] [Related]
10. Mouse tissues that undergo neoplastic progression after K-Ras activation are distinguished by nuclear translocation of phospho-Erk1/2 and robust tumor suppressor responses.
Parikh N; Shuck RL; Nguyen TA; Herron A; Donehower LA
Mol Cancer Res; 2012 Jun; 10(6):845-55. PubMed ID: 22532587
[TBL] [Abstract][Full Text] [Related]
11. Vav1 and mutant K-Ras synergize in the early development of pancreatic ductal adenocarcinoma in mice.
Salaymeh Y; Farago M; Sebban S; Shalom B; Pikarsky E; Katzav S
Life Sci Alliance; 2020 May; 3(5):. PubMed ID: 32277014
[TBL] [Abstract][Full Text] [Related]
12. Investigation of the structural requirements of K-Ras(G12D) selective inhibitory peptide KRpep-2d using alanine scans and cysteine bridging.
Niida A; Sasaki S; Yonemori K; Sameshima T; Yaguchi M; Asami T; Sakamoto K; Kamaura M
Bioorg Med Chem Lett; 2017 Jun; 27(12):2757-2761. PubMed ID: 28457754
[TBL] [Abstract][Full Text] [Related]
13. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
14. Dual Farnesyl and Geranylgeranyl Transferase Inhibitor Thwarts Mutant KRAS-Driven Patient-Derived Pancreatic Tumors.
Kazi A; Xiang S; Yang H; Chen L; Kennedy P; Ayaz M; Fletcher S; Cummings C; Lawrence HR; Beato F; Kang Y; Kim MP; Delitto A; Underwood PW; Fleming JB; Trevino JG; Hamilton AD; Sebti SM
Clin Cancer Res; 2019 Oct; 25(19):5984-5996. PubMed ID: 31227505
[TBL] [Abstract][Full Text] [Related]
15. [Specific immune against pancreatic cancer induced by dendritic cells pulsed with mutant K-ras peptide].
Yang B; He Y; Sun DL; Zou Y; Qin XH; Huang BH
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(28):1956-60. PubMed ID: 19062734
[TBL] [Abstract][Full Text] [Related]
16. CRISPR/Cas9-Mediated Knock-Out of Kras
Lentsch E; Li L; Pfeffer S; Ekici AB; Taher L; Pilarsky C; Grützmann R
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739488
[TBL] [Abstract][Full Text] [Related]
17. Dihydrosanguinarine suppresses pancreatic cancer cells via regulation of mut-p53/WT-p53 and the Ras/Raf/Mek/Erk pathway.
Wu SZ; Xu HC; Wu XL; Liu P; Shi YC; Pang P; Deng L; Zhou GX; Chen XY
Phytomedicine; 2019 Jun; 59():152895. PubMed ID: 30913453
[TBL] [Abstract][Full Text] [Related]
18. α-Mangostin-encapsulated PLGA nanoparticles inhibit pancreatic carcinogenesis by targeting cancer stem cells in human, and transgenic (Kras(G12D), and Kras(G12D)/tp53R270H) mice.
Verma RK; Yu W; Shrivastava A; Shankar S; Srivastava RK
Sci Rep; 2016 Sep; 6():32743. PubMed ID: 27624879
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status.
Chao MW; Chang LH; Tu HJ; Chang CD; Lai MJ; Chen YY; Liou JP; Teng CM; Pan SL
Clin Epigenetics; 2019 May; 11(1):85. PubMed ID: 31142371
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of potent pyruvate dehydrogenase kinase 4 inhibitors from plants in pancreatic cancer.
Tambe Y; Terado T; Kim CJ; Mukaisho KI; Yoshida S; Sugihara H; Tanaka H; Chida J; Kido H; Yamaji K; Yamamoto T; Nakano H; Omura S; Inoue H
Mol Carcinog; 2019 Oct; 58(10):1726-1737. PubMed ID: 31106493
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
